The National Biopharmaceutical Facility (NBF) Extends Research Efforts Towards Commercial Production

     The National Biopharmaceutical Facility (NBF) was established in 2008 through the collaboration of the National Center for Genetic Engineering and Biotechnology (BIOTEC), the National Science and Technology Development Agency (NSTDA), and King Mongkut’s University of Technology Thonburi (KMUTT). It serves as a connecting unit for researchers to pre-clinical and clinical phase I, II biopharmaceutical and vaccine testing.

     This facility encompasses units ranging from small-scale production development (greater than or equal to 5 liters), pilot-scale (5-30 liters) for both upstream processes (fermentation/cell cultivation) and downstream processes (purification), up to the prototype production facility with a maximum capacity of 2,000 liters. Furthermore, it is equipped with modern tools and laboratories for analyzing biopharmaceuticals and vaccines, ready to analyze characteristics from a basic level up to advanced techniques such as genetic sequence and protein analysis. This includes platforms for monoclonal antibody, a group of bioactive substances used in cancer treatment, plasmid DNA platform, and protein group platform for treating diseases such as PCV2d vaccine, a product of Thai collaboration by BIOTEC, KMUTT and a United Kingdom partner under the GCRF project.

     The NBF also collaborates to produce vaccines for pig diseases such as PEDV and PRRS that are prevalent in Thailand, and currently, it has produced a cell bank for virus cultivation at this prototype factory.

     For the Thai-UK project, the candidate vaccine for pigs is the Porcine Circovirus type 2d (PCV2d). It has been tested in small animals such as mice and rabbits, demonstrating that the prototype vaccine can stimulate animals to produce virus-specific immunity, including neutralizing antibodies that reduce viral infection in cell systems.

     Meanwhile, the NBF and University College London (UCL) have successfully developed and scaled up a 30-liter production process, capable of producing up to 200,000 doses of the PCV2d candidate vaccine per 30-liter batch. Trials are ongoing in pigs, and the results will be consulted with the Food and Drug Administration (FDA) for registering a domestically produced animal vaccine.

     The National Biopharmaceutical Facility (NBF) is an extension of research efforts to support the biomedical industry of government agencies in Thailand.

 

Source: National Science and Technology Development Agency (NSTDA)

Tel. +66 2564 7000

For more information


Comment

Copyright 2022, The Government Public Relations Department
Web Traffic Statistics : 29,801,357